Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
AstraZeneca enters the final three weeks before its October 30 results with positioning largely unchanged from last week's note: no short pressure, a stock trading near flat on the week, and the CEO's September open-market purchase still the most significant signal in the data.
The lending market remains one of the least charged in the large-cap pharma universe. Availability is essentially uncapped, with over 820 million shares available to borrow against negligible demand. The cost to borrow has actually moved in the opposite direction from last week, edging back up from 0.25% to 0.56%, though that remains firmly in low territory and well within normal noise for a stock of this size. Short interest is a rounding error, and the ORTEX short score of 25.4 ranks in the 96th percentile of the universe for lack of short conviction. There is nothing in the borrow market pointing at meaningful positioning pressure in either direction.
The valuation picture is straightforward for a large-cap pharma name. The stock trades at a trailing P/E of 14.4 and EV/EBITDA of 11.5, both of which have edged higher over the past 30 days alongside a modest price recovery. Price-to-book is 4.1. The factor profile is strongest on dividend score (89th percentile) and EPS momentum over 30 days (82nd percentile), with the short score rank (96th percentile) reflecting the near-complete absence of bearish positioning. EPS surprise ranks at the 40th percentile, suggesting the Street is less consistently wrong to the downside here than at some peers. The analyst data in the snapshot is too stale to quote, so no price target is carried here.
The insider story from the September 14 cluster is worth keeping in focus as the earnings date approaches. CEO Pascal Soriot bought 60,000 shares at 121.02p and Non-Executive Chair Michel Demaré added 2,500 shares on the same day. The stock closed this week at 121.8p, fractionally above the purchase price, meaning Soriot's roughly £7.3 million open-market bet is barely in the money. That both executives bought at the market rather than through compensation mechanisms gives the purchases more weight than the small grants the CFO received around the same time. Net insider activity over the past 90 days is 62,500 shares, all discretionary buying.
Among close peers, the week was broadly weak for the sector. GSK dropped 2.3% and JNJ fell 2.4%, while MRK gave back 1.7%. AstraZeneca's own 0.8% weekly decline was therefore a relative outperformance, though Novartis edged into positive territory, up around 0.1% on the week. Bayer was the notable laggard, off 8.3%.
The last earnings print, on July 27, saw the stock rise 2.1% on the day but give back 9.2% over the following five sessions, a pattern that makes the Q3 release on October 30 more about whether the quarterly results hold up under post-print scrutiny than about the immediate reaction. With the CEO's buy price sitting almost exactly at the current level, that threshold is the number to watch heading into the announcement.
See the live data behind this article on ORTEX.
Open AZN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
